학술논문

The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma
Document Type
article
Source
Transplantation and Cellular Therapy. 27(10)
Subject
Transplantation
Rare Diseases
Cancer
Hematology
Good Health and Well Being
Humans
Bone Marrow
Diterpenes
High-Throughput Nucleotide Sequencing
Multiple Myeloma
Neoplasm
Residual
Minimal residual disease
Immune profiling
Multiple myeloma
Endpoint
CAR T-cell
Cellular therapy
Language
Abstract
The fifth annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma was conducted as one of the American Society of Hematology Annual Meeting Scientific Workshops on Thursday December 3, 2020. This workshop focused on four main topics: (1) integrating minimal residual disease into clinical trial design and practice; (2) the molecular and immunobiology of disease evolution and progression in myeloma; (3) adaptation of next-generation sequencing, next-generation flow cytometry, and cytometry by time of flight techniques; and (4) chimeric antigen receptor T-cell and other cellular therapies for myeloma. In this report, we provide a summary of the workshop presentations and discuss future directions in the field.